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Nicolas Roche1*, Vicente Plaza2, Vibeke Backer 3, Job van der Palen4,5, Isa Cerveri6, Chelo Gonzalez7, Guilherme Safioti 8,
Irma Scheepstra8, Oliver Patino8 and Dave Singh9
Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic
obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma
disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS)
and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving
treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single
routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was
assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any
ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low
symptom burden (CAT score <10).
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INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are of
significant concern worldwide owing to their high prevalence and
substantial clinical and economic burden.1 While asthma is the
most prevalent respiratory disease in the world (and twice as
common as COPD), the mortality rate associated with COPD is
eight times higher than for asthma.1 The absolute number of
patients with these two conditions is increasing as the global
population grows.1
Inhaled medications are the mainstay of treatment for both
COPD and asthma,2,3 but many patients with asthma and COPD
have poor treatment adherence and/or inhaler technique.4,5
Improvements in these patient factors have the potential to
substantially increase the effectiveness of therapy and help
alleviate disease burden.6–9
Combined inhaled corticosteroid (ICS) and long-acting beta
agonist (LABA) treatments play a central role in the management
of persistent asthma (Step 3 and above)2 and have been
associated with beneficial effects on lung function, exacerbation
rates, and patient-reported outcomes compared with each
treatment alone in patients with COPD.10–12 Several inhalers
containing a fixed-dose combination (FDC) and ICS and LABA are
commercially available in Europe for the delivery of maintenance
therapies for COPD and/or asthma. The convenience of having
both substances in a single inhaler may help improve treatment
adherence and is often cost saving, compared with using two
separate inhalers.13 In April 2014, marketing authorisation was
granted for DuoResp® Spiromax®, a budesonide/formoterol
combination treatment alternative to the existing Symbicort
Turbuhaler, which contains the same active substances but uses
a different dry powder inhaler (DPI) mechanism with fewer
preparation manoeuvres.14
The present real-world observational study was conducted to
obtain a cross-sectional overview of asthma disease control and
COPD symptom burden among patients receiving treatment with
an FDC of ICS and LABA administered twice daily using a DPI.
Additional aims of the study were to evaluate patient adherence
in a real-world clinical practice population and to collect
information on the patients’ background and their healthcare
utilisation, in order to assess the relationship between these
factors and disease burden. Another purpose of the study was to
analyse clinical data among patients using the FDC budesonide/
formoterol DuoResp Spiromax inhaler. The data on DuoResp
Spiromax adherence, satisfaction, and ease of use will be reported
separately.
RESULTS
Study population
A total of 1138 patients with asthma were enrolled in the study.
Enrolment by country is presented in Supplementary Table 1.
Among asthma patients receiving treatment with any ICS/LABA,
1101 completed the study. The 4 most frequently used ICS/LABA
treatment devices (used by 72.0% of patients) were Symbicort
inhalers (298 patients), DuoResp Spiromax inhalers (235 patients),
Seretide inhalers (174 patients), and Fostair inhalers (86 patients).
Other types of fixed-dose ICS/LABA inhalers were used by 28.0%
of patients.
A total of 596 patients with COPD were enrolled in the study.
Enrolment by country is presented in Supplementary Table 1. Of
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these, 560 COPD patients completed the study. The four most
frequently used ICS/LABA treatment devices (used by 74.5% of
patients) were Seretide inhalers (156 patients), Symbicort inhalers
(113 patients), DuoResp Spiromax inhalers (107 patients), and
Fostair inhalers (41 patients). Other types of fixed-dose ICS/LABA
inhalers were used by 25.5% of patients.
Patient demographics are presented in Table 1a. The mean
(standard deviation [SD]) age of the asthma cohort was 53.8 (16.7)
years, and asthma was less frequent in men (37.1%) than women
(62.9%). The mean (SD) age of the COPD cohort was 69.5 (9.0)
years. This group included more men (62.5%) than women
(37.5%). Disease characteristics for all patients are presented in
Table 1b (additional information regarding previous asthma/COPD
treatments is supplied in Supplementary Table 2). The mean (SD)
last known forced expiratory volume in 1 s (FEV1) % predicted was
81.7% (23.1) in the asthma cohort and 58.3% (23.6) in the COPD
group.
Primary endpoints
In the overall asthma population, 684 patients (62.4%) had an
Asthma Control Test (ACT) score >19 and were considered to have
achieved disease control at the time of the assessment, after
≥3 months of FDC inhaler use (Fig. 1). In the overall COPD
population, 85 patients (15.5%) had a COPD Assessment Test
(CAT) score <10, defining a low symptom burden at the time of
the assessment, after ≥3 months of FDC inhaler use (Fig. 2).
Secondary endpoints
Table 2 shows an overview of patient adherence to treatment as
assessed by Morisky Medication Adherence Scale (MMAS-8®)
questionnaire. A greater proportion of patients in the COPD group
had high adherence compared with patients in the asthma group
(51.0% vs 34.4%, respectively). Table 3 provides an overview of
health status among SPRINT study participants, based on the
EuroQoL 5-dimensional 3-level (EQ-5D-3L) questionnaire findings.
Mean (SD) visual analogue scale (VAS) score was greater in
patients with asthma than in those with COPD (74.3 [18.3] vs 62.8
[18.5], respectively). The mean (SD) raw EQ-5D-3L index value was
also greater in asthma patients than in those with COPD (80.1
[18.5] vs 70.7 [20.5], respectively). Table 4 shows correlations
between adherence and health-related quality of life measures.
Table 5 shows health-related quality of life measures according to
achievement or otherwise of asthma disease control or COPD low
symptom burden.
Healthcare resource utilisation in the 3 months preceding the
study was determined. In the total cohort, asthma- or COPD-
related visits to a physician (median 0, range 0–10) and
emergency department (median 0, range 0–6) and hospitalisa-
tions lasting >1 day (median 0, range 0–11) were rare events.
DISCUSSION
The results of this observational study of patients receiving
inhaled maintenance treatment with ICS/LABA FDC showed that
almost two-thirds of asthma patients met the threshold for
asthma control (ACT score >19). The rate of asthma control in the
SPRINT study (62.4%) was higher than the pan-European rate
reported in the International Cross-Sectional and Longitudinal
Assessment on Asthma Control (LIAISON) studies conducted in
2012–2013 (43.5%)15 and the 2014 REcognise Asthma and LInk to
Symptoms and Experience (REALISE) study conducted across
Europe (20%).16
Research has shown that asthma patients’ perceptions of
disease control are often at odds with more objective measures
of disease control. For example, >80% of patients in the REALISE
study considered their asthma to be controlled, and more than
two-thirds did not consider their condition as serious, whereas in
fact only one patient in five met the criteria for controlled
asthma.16 This underestimation of disease control probably has a
significant impact on asthma outcomes. A report by the Royal
College of Physicians in the UK estimated that >65% of asthma
deaths were associated with potentially preventable factors,
including trigger avoidance, medication adherence, and regular
medical follow-up.17
Comparatively few patients in the SPRINT study (15.5%) met the
pre-defined criterion for low COPD symptom burden (CAT score
<10). A recently reported multicentre, observational study in
Europe classified 21% of COPD patients as ‘controlled’, using the
same CAT score criteria.18 However, all patients classified had
mild-to-moderate COPD. Most patients in the SPRINT cohort were
elderly (median age 70 years). As symptoms become more difficult
to manage as COPD progresses, the low rate of achievement of
the pre-defined CAT score threshold in the SPRINT study COPD
cohort is not unexpected. Taken together, these results suggest
that a CAT threshold of 10 is probably too low to define low COPD
symptom burden.18,19 In view of the lack of reversibility that is
typical of COPD, the threshold might need to be adapted to the
baseline severity of the disease.
Significant negative effects of COPD on health-related quality of
life are reflected in the health status scores reported among
SPRINT study participants. For example, the mean EQ-5D-3L for a
70-year-old person (mean age of the COPD cohort) living in the
European countries that were included in the SPRINT study is
between 69.0 and 81.5,20 whereas the mean EQ VAS in our COPD
cohort was 62.8. Asthma appeared to have less effect on overall
health status; the mean EQ VAS in our asthma cohort was 74.3,
which is within the average range for a 55-year-old person living
in these European countries (72.0–81.7).20
The findings of the SPRINT study indicate that suboptimal
adherence to inhaled treatment regimens is widespread among
patients with asthma and COPD. In particular, only 34.4% of
patients with asthma had an MMAS-8 score indicative of high
adherence, and >30% had a score indicative of low adherence.
Poor adherence leading to poor outcomes in patients with asthma
was also seen in the LIAISON study, which used the 4-item Morisky
Medication Adherence Scale (MMAS-4) and found that patients
with uncontrolled asthma were more likely to have MMAS-4
scores indicative of low adherence than those with controlled
asthma.15 Consistent with previous reports of relatively inferior
adherence among younger vs older patients using inhaled
medications,21 SPRINT study participants with COPD were more
likely than those with asthma to be adherent, with more than half
having an MMAS-8 score indicative of high adherence. The rates
of adherence and asthma control among participants in the
SPRINT study were consistent with other recent reports of real-
world studies in both asthma and COPD cohorts.7,22 As expected,
adherence was markedly lower than is typically seen in clinical
trials.
Relationships between disease control and other variables were
explored for asthma patients using multiple regression. Although
no model could be found that could explain most of the variance
in the data, analysis findings suggested that male sex and higher
education may be positively associated, and body mass index
(BMI) negatively associated, with disease control. These observa-
tions are consistent with previous findings.23,24
Previous research has linked adherence with clinical symptoms
and outcomes.4,25–27 However, even in adherent patients, other
factors may influence outcomes. For example, inhaler technique is
an important determinant of outcome, as it influences the dose of
drug delivered to the lungs at each inhalation.6 Demographic
factors may also influence disease control. For example, the
LIAISON study found that females, those aged 40–64 years, and
patients who were overweight or obese were less likely to achieve
asthma control compared with males, other age groups, and those
of normal weight, respectively.15 Other studies have confirmed the
N Roche et al.
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Table 1. (a) Patient demographic characteristics and (b) clinical characteristics, concomitant conditions, and prior medications.
Asthma (N= 1101) COPD (N= 560) Total (N= 1661) p value
(a)
Gender, n (%)
Female 693 (62.9) 210 (37.5) 903 (54.4) <0.001
Male 408 (37.1) 350 (62.5) 758 (45.6)
Age at study visit, years
Mean (SD) 53.8 (16.7) 69.5 (9.0) 59.1 (16.3) <0.001
BMI, kg/m2
Mean (SD) 28.1 (6.1) 27.8 (5.9) 28 (6.0) 0.258
Data unavailable 71 26 97
Obesity (BMI ≥30), n (%)
Yes 315 (30.6) 161 (30.1) 476 (30.4) 0.906
No 715 (69.4) 373 (69.9) 1088 (69.6)
Data unavailable 71 26 97
(b)
Years since disease diagnosis
Median (P25, P75) 11 (4, 23) 7 (4, 12) 9 (4, 18) <0.001
Data unavailable 14 4 18
FEV1, L
Mean (SD) 2.5 (0.9) 1.5 (0.6) 2.1 (1.0) <0.001
Data unavailable 186 36 222
% predicted FEV1, %
Mean (SD) 81.7 (23.1) 58.3 (23.6) 73.1 (25.9) <0.001
Data unavailable 224 50 274
Concomitant disease presence, n (%)
Yes 792 (73.1) 459 (83.5) 1251 (76.6) <0.001
No 292 (26.9) 91 (16.5) 383 (23.4)
Data unavailable 17 10 27
Concomitant diseasea, n (%) (N= 1084) (N= 550) (N= 1634)
Cardiovascular disease 267 (24.6) 269 (48.9) 536 (32.8) <0.001
Depression or anxiety disorder 126 (11.6) 79 (14.4) 205 (12.5) 0.133
Allergy 304 (28) 26 (4.7) 330 (20.2) <0.001
Osteoporosis 33 (3.0) 37 (6.7) 70 (4.3) <0.001
Diabetes 91 (8.4) 84 (15.3) 175 (10.7) <0.001
Cancer 42 (3.9) 53 (9.6) 95 (5.8) <0.001
Other 430 (39.7) 276 (50.2) 706 (43.2) <0.001
Any previous asthma/COPD treatment, n (%)
Yes 575 (56.3) 283 (55.1) 858 (55.9) 0.679
No 446 (43.7) 231 (44.9) 677 (44.1)
Data unavailable 80 46 126
Previous asthma/COPD treatment description, n (%) (n= 575) (n= 283) (n= 858)
ICS monotherapy 191 (33.2) 23 (8.1) 214 (24.9) <0.001
LABA monotherapy 20 (3.5) 21 (7.4) 41 (4.8)
Fixed-dose combination (different from current) 287 (49.9) 147 (51.9) 434 (50.6)
Long-acting muscarinic antagonists 13 (2.3) 60 (21.2) 73 (8.5)
Leukotriene modifier 28 (4.9) 0 (0) 28 (3.3)
Methylxanthine (theophylline) 1 (0.2) 5 (1.8) 6 (0.7)
Other 35 (6.1) 27 (9.5) 62 (7.2)
Data unavailable 0 0 0
Duration (months) of use of the patient’s current FDCb
Median (P25, P75) 18.7 (8.6, 47.2) 22.4 (10.1, 55.1) 19.7 (9, 50.4) 0.144
Data unavailable 225 130 355
Disease control (asthma)/Low symptom burden (COPD), n (%)
Yes 684 (62.4) 85 (15.5) 769 (46.7) <0.001
No 412 (37.6) 464 (84.5) 876 (53.3)
Data unavailable 5 11 16
BMI body mass index, COPD chronic obstructive pulmonary disease, FDC fixed-dose combination, FEV1 forced expiratory volume in 1 s, ICS inhaled
corticosteroid, LABA long-acting beta agonist, SD standard deviation
aEvery patient may present several concomitant diseases. Thus percentages have been calculated based on the number of patients
bPatients were eligible for the study if they had received a stable dose of ICS/LABA FDC for the 3 months prior to enrolment. One COPD patient who had
received treatment for 12 weeks was accepted onto the study by the sponsor
N Roche et al.
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interaction between obesity and disease control in asthma. Scott
et al. showed that, among asthma patients who are adherent to
therapy, those who are obese (BMI >30mg/m2) have difficulty
achieving asthma control.28 Thirty percent of patients in the
SPRINT cohort had a BMI >30 kg/m2, and the proportion of obese
patients was similar in the asthma (30.6%) and COPD (30.1%)
cohorts. This is slightly higher than the proportion of obese
patients reported in the LIAISON study of European asthma
patients (26.1%).15
COPD patient demographics showed that participants receiving
an ICS/LABA FDC in this study covered the range of COPD
subtypes encountered in routine clinical practice (elderly, former
or current smokers, high incidence of comorbidity).29,30 Owing to
the stringent selection criteria that are typically applied, rando-
mised clinical trial cohorts are poorly representative of the broader
COPD population, most of whom are treated in primary care.31,32
Comorbidities, which may be a reason to exclude patients from
randomised clinical trials,32 were present in 83.5% of COPD
patients in the SPRINT study. This is higher than the prevalence of
significant comorbidity reported in a Norwegian study of COPD
patients seen in primary care or hospital outpatient clinics
(60.7%)32 but lower than the prevalence reported in US COPD
patients (96.4%), according to the National Health and Nutrition
Examination Survey, 1999–2008.30 Furthermore, the mean age of
COPD patients in the SPRINT study, 69.5 years, was markedly
higher than is typical for large randomised COPD studies, for
which Kruis and colleagues reported a mean age of 63.7 years.31
Strengths of the SPRINT study include the pan-European
context, involving 10 countries from across Europe, and the
generalisability to the population of patients seen in everyday
clinical practice. The study included all patients with asthma or
COPD receiving twice-daily ICS/LABA FDC and did not exclude
anyone on demographic or clinical grounds. Another strength is
the inclusion of patient-reported outcome measures that are
widely used and validated in COPD and asthma populations.33
However, the SPRINT study also has some limitations. As an
observational study, it is subject to confounders and potential
bias. For example, assessments by patients were subject to recall
bias and reporting bias (e.g. with regard to adherence). Wherever
possible, attempts were made to minimise recall bias by using
patient records to assess preceding medical visits. In addition, this
study was not designed to assess the comparative effectiveness of
different ICS/LABA FDC inhalers, and the findings likely describe a
class effect rather than the effect of any specific type of inhaler.
The results of this observational clinical study showed that the
majority (62%) of asthma patients using ICS/LABA FDC inhalers
meet the threshold for asthma control in real-world clinical
practice and that the burden of symptoms for COPD in real-world
clinical practice is high. Adult patients with asthma and COPD
have a high rate of comorbidities, but adherence to ICS/LABA
therapy in real-world asthma and COPD patients is low.
Asthma control among patients using FDC ICS/LABA   
Achieved control
(ACT score >19)
Did not achieve control 
(ACT score ≤19) 
37.6%
62.4%
N = 1096*
Fig. 1 Proportion of asthma patients with disease control,
defined as ACT score >19, at the time of assessment after at
least 3 months of FDC inhaler use. *Data were unavailable for 5
patients. ACT Asthma Control Test, FDC fixed-dose combination.
COPD symptom burden among patients using FDC ICS/LABA   
Had low symptom burden
(CAT score <10)
Did not have low symptom 
burden (CAT score ≥10) 
N = 549*
15.5%
84.5%
Fig. 2 Proportion of COPD patients with low symptom burden,
defined as CAT score <10, at the time of assessment, after at least
3 months of FDC inhaler use. *Data were unavailable for 11
patients. CAT COPD Assessment Test, COPD chronic obstructive
pulmonary disease, FDC fixed-dose combination.
Table 2. Adherence to ICS/LABA treatment among SPRINT study participants with asthma and COPD, as assessed by MMAS-8 score and adherence
classification.
Asthma (N= 1101) COPD (N= 560) Total (N= 1661) p value
MMAS-8 score
All ICS/LABA (n= 1101) (n= 560) (n= 1661)
Median (P25, P75) 7.0 (5.8, 8.0) 8.0 (7.0, 8.0) 7 (5.8, 8) <0.001
Data unavailable 21 9 30
MMAS-8 adherence classification, n (%)
All ICS/LABA (n= 1101) (n= 560) (n= 1661)
High (score= 8) 371 (34.4) 281 (51.0) 652 (40) <0.001
Medium (6 ≤ score < 8) 382 (35.4) 182 (33.0) 564 (34.6)
Low (score < 6) 327 (30.3) 88 (16.0) 415 (25.4)
Data unavailable 21 9 30
COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroid, LABA long-acting beta agonist, MMAS-8 8-item Morisky Medication Adherence Scale
Note: Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, ScM,
MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA, 90095-1772
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In conclusion, this large, observational study in adult patients
with asthma and COPD across 10 countries in Europe found that
more than half of asthma patients using any ICS/LABA FDC inhaler
met the threshold for asthma disease control. The pre-defined
threshold for low symptom burden was met by few patients with
COPD; however, this is probably to be expected in a chronic
disease with an overall more advanced patient population than for
asthma. Suboptimal adherence was widespread, particularly
among asthma patients. Both patient populations had a high
rate of comorbidities, and many of the patients would have been
ineligible to participate in recent randomised controlled trials of
asthma and COPD medications. The findings of the SPRINT study
highlight the need for more attention by European physicians on
patient-reported symptoms and adherence in the asthma and
COPD patients they see in clinical practice.
METHODS
Study design and participants
This was a Phase IV, multi-country, observational, prospective study in
patients with asthma or COPD who were on a stable dose of ICS/LABA FDC
administered by DPI twice daily. The study was performed between May
2015 and April 2017 at 140 centres in Croatia (15 sites), Denmark (7),
Ireland (7), Italy (25), The Netherlands (7), Norway (4), Portugal (10), Spain
(39), Sweden (2), and the UK (24). Prior to study initiation, Independent
Ethics Committee approval was obtained from all relevant national or
regional bodies.
Data were collected for the whole population of patients receiving any
ICS/LABA treatment in a routine setting (on a single occasion during an
otherwise normal visit to a physician’s office or clinic). Participating
physicians did not perform any additional medical procedures, other than
those that were part of routine practice. All treatment decisions were at the
sole discretion of participating physicians.
Patients
Patients were eligible to participate if they had a diagnosis of persistent
asthma or COPD in accordance with the GINA or GOLD reports,
respectively, and were receiving treatment with a stable dose of an ICS/
LABA FDC, administered twice daily by DPI for 3 months prior to
enrolment. Dose stability was defined as no change in dose by >50% in the
past 3 months. Patients with asthma were eligible to participate if they
were aged ≥18 years, and those with COPD could participate if they were
aged ≥40 years and/or a current or ex-smoker with a smoking history of
>10 pack-years. In addition, all participants had to agree to participate in
the study and to disclose any medical events to the treating physician and
to be willing and able to provide written informed consent and complete
the questionnaires. The only exclusion criterion was that patients could not
currently be, or plan to be, enrolled in an interventional study.
Assessments
Demographic and clinical characteristics (including medical history,
previous and concomitant respiratory medications, number of exacerba-
tions in the previous year, and healthcare utilisation in the past 3 months)
were collected from the patient’s medical records by the investigational
centres. During the study visit, the patient’s respiratory disease burden was
evaluated by a series of paper questionnaires, completed by patients in
their local language. Asthma disease control was assessed using the ACT
questionnaire.34 The burden of COPD symptoms was evaluated using
CAT.35 Patients rated their own adherence to therapy using the MMAS-8
questionnaire.36–38 Patients also rated their general health status using the
EQ-5D-3L questionnaire.39 The two-part questionnaire is comprised of the
EQ-5D descriptive system and the EQ VAS, which measure 5 dimensions
(mobility, self-care, usual activities, pain/discomfort, anxiety/depression) on
a 3-point scale and self-rated health on a VAS, respectively.
Endpoints
The primary endpoint was the percentage of patients whose respiratory
disease was well controlled, which was defined as having an ACT score >19
in patients with asthma and low symptom burden (defined as CAT score
<10) in patients with COPD. Secondary endpoints were self-reported
adherence based on the MMAS-8 score, health status defined by the EQ-
5D-3L, and recent healthcare resource utilisation in terms of physician
visits, emergency room visits, and hospitalisations lasting >1 day for
asthma or COPD.
Statistical analyses
A target sample size of approximately 792 patients with asthma and 648
patients with COPD was planned. Based on the calculated sample size, the
half-width of the 95% confidence interval for the proportion of patients
with asthma with controlled disease is 0.035 for all patients treated with
ICS/LABA. Similarly, based on this sample size, the half-width of the 95%
confidence interval for the proportion of patients with COPD with low
symptom burden (considered controlled disease) is 0.032 for all patients
treated with ICS/LABA. Statistical analysis was based on the Safety Set,
Table 3. Health-related quality of life and healthcare utilisation among SPRINT study participants with asthma and COPD.
Asthma
(N= 1101)
COPD
(N= 560)
Total
(N= 1661)
p value
VAS score
Mean (SD) 74.3 (18.3) 62.8 (18.5) 70.4 (19.1) <0.001
Data unavailable 26 7 33
Mean EQ-5D-3L index value
Mean (SD) 0.80 (0.21) 0.69 (0.23) 0.76 (0.23) <0.001
Data unavailable 17 4 21
Number of visits to the doctor/GP due to asthma or COPD
Mean (SD) 0.4 (0.8) 0.7 (1.2) 0.5 (1) <0.001
Data unavailable 0 0 0
Number of emergency department visits due to asthma or COPD
Mean (SD) 0 (0.2) 0.1 (0.5) 0.1 (0.3) 0.006
Data unavailable 0 0 0
Number of hospital stays (>1 day) due to asthma or COPD
Mean (SD) 0 (0.2) 0.1 (0.8) 0.1 (0.5) <0.001
Data unavailable 0 0 0
COPD chronic obstructive pulmonary disease, EQ-5D-3L EuroQoL 5-dimensional 3-level, SD standard deviation, VAS visual analogue scale
N Roche et al.
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which included all patients enrolled in the study in accordance with the
inclusion criteria.
All data (including demographic characteristics, medical history,
previous and concomitant respiratory medications, primary and secondary
outcome variables, number of exacerbations in the previous year, and
healthcare utilisation in the past 3 months) were summarised descriptively
using number and percentage for categorical variables and mean (SD) or
median and 25th and 75th percentiles, as appropriate, for continuous
variables.
Test parameters for hypothesis testing are summarised in Supplemen-
tary Table 3. Chi-square test (or Fisher’s exact test when applicable) was
used for comparisons between categorical variables. Comparison of
continuous variables between two groups (e.g. cohorts) was performed
by means of t test. Hypotheses for t test were assessed using
Kolmogorov–Smirnov test with Lilliefors correction (normality) and Levene
test (homoscedasticity). If homoscedasticity failed, Welch t test was
considered instead; if normality failed, Wilcoxon test was considered,
whether homoscedasticity failed or not. Pearson correlation was con-
sidered to assess the relationship between two continuous variables. If
normality failed, Spearman and Kendall correlation were obtained instead.
Unless otherwise stated, p values were two sided. For both the chi-square
test and Fisher’s exact test, Phi was obtained as a measure of the effect size
for 2 × 2 tables and Cramer’s V for tables with more than 2 rows. For the t
test and Wilcoxon test, Cohen’s d and Cliff’s delta were provided,
respectively, as a measure of the effect size.
In an exploratory analysis, multiple regression models were constructed
to analyse the relationship between the dependent variable “disease
control” variable (based on ACT or CAT scores) and several independent
variables (age, gender, BMI, smoking, education, adherence, and
comorbidity).
At the end of the study, all data were pooled, and global analysis
performed (additional analyses for each country, and intercountry
differences were also performed in a post hoc exploratory analysis). No
imputation was made for missing data.
Ethics approval
The study protocol was approved by the Hospital Universitario de Canarias,
Spain; Lakemedelsverket and the National Ethics Committee, Sweden; 25
local Ethics Committees in Italy; The Foundation for the Code for
Pharmaceutical Advertising, Netherlands; 10 local Ethics Committees in
Portugal; one National Ethics Committee in the UK; one National Ethics
Committee in Ireland; and one National Ethics Committee in Croatia.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
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